Posted inClinical Updates Diabetes & Endocrinology news
Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence
This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesity, with a consistent safety profile.
